Trial · NCT07904806
Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
NCT07904806, Phase 2, Not yet recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Trials, record NCT07904806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- NCT number
- NCT07904806
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 75 participants, estimated
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- VIS954, Standard Of Care (SOC), Placebo
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Participants in Remission at Week 24 | Week 24 | A participant is considered to be in remission at Week 24 if the Birmingham Vasculitis Activity Score version 3 (BVAS v3) is 0 at Week 24 and no rescue medication was required. BVAS v3 is a measure of vasculitis disease activity, with a score of 0 indicating no active disease. |
| Primary | Incidence of Treatment-Emergent Adverse Events (TEAEs) Through Week 24 | Baseline through Week 24 | TEAEs will be classified according to severity and seriousness and summarized through Week 24. Participants may experience more than one TEAE. |
| Secondary | Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters Through Week 24 | Baseline through Week 24 | |
| Secondary | Number of Participants With Clinically Significant Changes in Vital Signs Through Week 24 | Baseline through Week 24 | |
| Secondary | Number of Participants With Clinically Significant Changes in Physical Examination Findings Through Week 24 | Baseline through Week 24 | |
| Secondary | Number of Participants With Clinically Significant Injection Site Reactions Through Week 24 | Baseline through Week 24 | |
| Secondary | Incidence of TEAEs Through Week 52 | Baseline through Week 52 | TEAEs will be classified according to severity and seriousness and summarized through Week 52. Participants may experience more than one TEAE. |
| Secondary | Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) | Baseline through Week 24 | Change from baseline in estimated glomerular filtration rate through Week 24. |
| Secondary | Time to Remission | Up to Week 24 | Time to remission is defined as the time to achieve a BVAS v3 score of 0. BVAS v3 measures disease activity in systemic vasculitis, with higher scores indicating greater disease activity. A score of 0 indicates no active disease. |
| Secondary | Duration of Remission | Up to Week 24 | Duration of Remission is defined as the time from the first achievement of a BVAS v3 score of 0 on or before Week 24 to the first major relapse. Relapse is classified as major or minor based on recurrent disease activity following remission, as assessed using BVAS v3 criteria. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904806
GET https://conductscience.org/api/trials/v1/NCT07904806/registered